This supports the concept that PKCα-D463H may regulate transcription through targetable epigenetic mechanisms, providing a potential clinical strategy for PRKCA mutant choroid glioma, particularly as BET domain inhibitors have been proposed for use in other glioma settings (35). The gene discussed is PRKCA; the disease is central nervous system cancer.